The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

As the prostate cancer treatment landscape continues to evolve, understanding the risks and benefits of each approach is critical for patients.

Completing treatment for head and neck cancer is a milestone, but recovery is an ongoing journey. With follow-ups, ...

The committee recommended Keytruda's subcutaneous form for all indications and as neoadjuvant/adjuvant treatment in PD-L1-positive head and neck cancer.

Please provide your email address to receive an email when new articles are posted on . Men who have depression before prostate cancer diagnosis may have significantly greater risk for death than ...